Skip to main content Back to Top
Advertisement

12/12/2019

Furosemide Tablets

Reason for the Shortage

    • Major discontinued furosemide tablets in early-2018.
    • Mylan did not provide a reason for the shortage.
    • Hikma states the shortage was due to manufacturing delays.
    • Sandoz discontinued furosemide tablets in late-August 2017.
    • Teva discontinued furosemide tablets in June 2018.

Available Products

    • Lasix oral tablet, Validus Pharmaceuticals, 20 mg, bottle, 100 count, NDC 30698-0067-01
    • Lasix oral tablet, Validus Pharmaceuticals, 40 mg, bottle, 50 count, NDC 30698-0066-05
    • Lasix oral tablet, Validus Pharmaceuticals, 40 mg, bottle, 100 count, NDC 30698-0060-01
    • Furosemide oral tablet, Hikma, 20 mg, bottle, 100 count, NDC 00054-4297-25
    • Furosemide oral tablet, Hikma, 20 mg, bottle, 1000 count, NDC 00054-4297-31
    • Furosemide oral tablet, Hikma, 20 mg, unit-dose blister pack, 100 count, NDC 00054-8297-25
    • Furosemide oral tablet, Hikma, 40 mg, bottle, 100 count, NDC 00054-4299-25
    • Furosemide oral tablet, Hikma, 40 mg, bottle, 1000 count, NDC 00054-4299-31
    • Furosemide oral tablet, Hikma, 40 mg, unit-dose blister pack, 100 count, NDC 00054-8299-25
    • Furosemide oral tablet, Hikma, 80 mg, bottle, 100 count, NDC 00054-4301-25
    • Furosemide oral tablet, Hikma, 80 mg, bottle, 500 count, NDC 00054-4301-29
    • Furosemide oral tablet, Hikma, 80 mg, unit-dose blister pack, 100 count, NDC 00054-8301-25
    • Furosemide oral tablet, Mylan, 20 mg, bottle, 100 count, NDC 00378-0208-01
    • Furosemide oral tablet, Mylan, 20 mg, bottle, 1000 count, NDC 00378-0208-10
    • Furosemide oral tablet, Mylan, 20 mg, unit-dose blister pack, 100 count, NDC 51079-0072-20
    • Furosemide oral tablet, Mylan, 40 mg, bottle, 100 count, NDC 00378-0216-01
    • Furosemide oral tablet, Mylan, 40 mg, bottle, 1000 count, NDC 00378-0216-10
    • Furosemide oral tablet, Mylan, 80 mg, bottle, 100 count, NDC 00378-0232-01
    • Furosemide oral tablet, Mylan, 80 mg, bottle, 1000 count, NDC 00378-0232-05

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated December 12, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 8, 2017 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT